John A. Kollins - 03 Jun 2022 Form 4 Insider Report for Satsuma Pharmaceuticals, Inc.

Role
President and CEO, Director
Signature
/s/ Thomas P. O'Neil as Attorney in Fact for John A. Kollins
Issuer symbol
N/A
Transactions as of
03 Jun 2022
Net transactions value
$0
Form type
4
Filing time
07 Jun 2022, 17:38:51 UTC
Next filing
08 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STSA Stock Option (Right to Buy) Award $0 +505,000 $0.000000 505,000 03 Jun 2022 Common Stock 505,000 $3.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty Five Percent (25%) of the shares subject to the option vest one year measured from June 3, 2022 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.